Enveric Biosciences
ENVB
26 hedge funds and large institutions have $4.45M invested in Enveric Biosciences in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
718% more call options, than puts
Call options by funds: $368K | Put options by funds: $45K
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
44% more funds holding
Funds holding: 18 → 26 (+8)
0% more ownership
Funds ownership: 0% → 0% (+0%)
4% less capital invested
Capital invested by funds: $4.64M → $4.45M (-$195K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$1.15M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$618K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$618K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$422K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$408K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$56.2K |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$42.2K |
| 3 |
Squarepoint
New York
|
-$27K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RI
26
Rinkey Investments
San Diego,
California
| $5K | +$14.1K | +1 | New |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $4K | – | – | – |
|
28
Simplex Trading
Chicago,
Illinois
| $2K | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
30
Squarepoint
New York
| – | -$27K | -1 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$7K | – | – |
|
ENVB Hedge Fund Activity: Q4 2021 in Review
26 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2021, worth a combined $4.45M — down 4.2% from $4.64M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ENVB positions and 1 closed out — a net gain of 8 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $1.15M. The largest seller was Integrated Wealth Concepts, cutting an estimated $56.2K.
- 26 institutional investors held Enveric Biosciences (ENVB) as of Q4 2021, up from 18 in Q3 2021.
- Funds reported $4.45M of Enveric Biosciences stock for Q4 2021, down 4.2% quarter-over-quarter.
- 9 funds opened new Enveric Biosciences positions in Q4 2021 and 1 closed out, a net change of +8 holders.
- The largest Enveric Biosciences buyer in Q4 2021 was Pura Vida Investments, an estimated $1.15M added.
- The largest Enveric Biosciences seller in Q4 2021 was Integrated Wealth Concepts, an estimated $56.2K sold.
Based on aggregated 13F filings for Q4 2021.